{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:23:18Z","timestamp":1791181398874,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ruxolitinib is JAK1\/JAK2 inhibitor with established clinical benefit in myelofibrosis (MF). We analyzed long-term outcomes of 107 patients with intermediate-2 or high-risk MF receiving ruxolitinib at MD Anderson Cancer Center (MDACC) on phase 1\/2 trial. After a median of 32 months of follow-up, 58 patients (54%) were still receiving ruxolitinib, with overall survival (OS) of 69%. The splenomegaly and symptom reductions achieved with ruxolitinib were sustained with long-term therapy. Therapy was well tolerated; discontinuation rates at 1, 2, and 3 years were 24%, 36%, and 46%, respectively. OS of 107 MDACC patients was significantly better (P = .005) than that of 310 matched (based on trial enrollment criteria) historical control patients, primarily because of highly significant difference in OS in the high-risk subgroup (P = .006). Furthermore, among MDACC patients, those with high-risk MF experienced the same OS as those with intermediate-2 risk. Patients with \u2265 50% reduction in splenomegaly had significantly prolonged survival versus those with &lt; 25% reduction (P &lt; .0001). Comparison of discontinuation rates and reasons for stopping the therapy to those reported for other 51 patients in the phase 1\/2 trial, and 155 ruxolitinib-treated patients in phase 3 COMFORT-I study, suggest that continued therapy with ruxolitinib at optimal doses contributes to the benefits seen, including OS benefit.<\/jats:p>","DOI":"10.1182\/blood-2012-02-414631","type":"journal-article","created":{"date-parts":[[2012,6,21]],"date-time":"2012-06-21T09:07:31Z","timestamp":1340269651000},"page":"1202-1209","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":199,"title":["Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls"],"prefix":"10.1182","volume":"120","author":[{"given":"Srdan","family":"Verstovsek","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Estrov","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautham","family":"Borthakur","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Rumi","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Pungolino","sequence":"additional","affiliation":[{"name":"Hematology, Niguarda Ca' Granda Hospital, Milan, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Morra","sequence":"additional","affiliation":[{"name":"Hematology, Niguarda Ca' Granda Hospital, Milan, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Caramazza","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[{"name":"Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111808333250000_B1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients.","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"issue":"13","key":"2019111808333250000_B2","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111808333250000_B3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111808333250000_B4","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"key":"2019111808333250000_B5","article-title":"Jakafi (ruxolitinib) full prescribing information.","year":"2011"},{"issue":"4","key":"2019111808333250000_B6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/cncr.26359","article-title":"Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.","volume":"15","author":"Quintas-Cardama","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"2019111808333250000_B7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"2019111808333250000_B8","article-title":"Comparison of the efficacy of placebo and best available therapy for the treatment of myelofibrosis in the COMFORT studies [abstract].","volume":"118","author":"Mesa","year":"2011","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"22","key":"2019111808333250000_B9","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","article-title":"How I treat symptomatic splenomegaly in patients with myelofibrosis.","volume":"113","author":"Mesa","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111808333250000_B10","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2019111808333250000_B11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808333250000_B12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","article-title":"Outcome of transplantation for myelofibrosis.","volume":"16","author":"Ballen","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9464","key":"2019111808333250000_B13","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"2019111808333250000_B14","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111808333250000_B15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"12","key":"2019111808333250000_B16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111808333250000_B17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111808333250000_B18","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMc1109555","article-title":"Long-term outcome of treatment with ruxolitinib in myelofibrosis.","volume":"365","author":"Tefferi","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111808333250000_B19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2019111808333250000_B20","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"issue":"5","key":"2019111808333250000_B21","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111808333250000_B22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time.","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"2019111808333250000_B23","article-title":"Improving survival trends in primary myelofibrosis: an international study [prepublished online ahead of print July 23, 2012].","author":"Cervantes","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111808333250000_B24","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1002\/cncr.26129","article-title":"Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.","volume":"117","author":"Mesa","year":"2011","journal-title":"Cancer"},{"key":"2019111808333250000_B25","first-page":"256","article-title":"Myeloproliferative disorders: JAK2 and beyond.","volume-title":"American Society of Clinical Oncology 2011 Educational Book","author":"Verstovsek","year":"2011"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/6\/1202\/1362322\/zh803212001202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/6\/1202\/1362322\/zh803212001202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T08:57:27Z","timestamp":1574067447000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/6\/1202\/30516\/Longterm-outcomes-of-107-patients-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,9]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,8,9]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-02-414631","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,9]]}}}